Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$MCTC News--Products going to Market!
Cannabis Global Directs Focus to Marketing Phase with Innovate Hemp Extract Product Lines
LOS ANGELES, CA -- July 7, 2020 -- InvestorsHub NewsWire -- Cannabis Global, Inc. (OTC: MCTC) ("Cannabis Global" or the "Company"), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, announces the completion of initial product development of the Hemp You Can Feel™ product lines, and the launch of the next phase of the Company's operations, which will focus on bringing the product lines to the marketplace. Over the coming weeks, Cannabis Global will be launching several new product marketing initiatives designed to move its innovative hemp extract and rare cannabinoid products into the marketplace.
"It has been approximately one year since we reorganized the Company, which today is known as Cannabis Global, Inc. During the first year, we concentrated on designing products that are distinct from the competition with established advantageous barriers," commented CEO Arman Tabatabaei. "We are very pleased with the results in that we not only have a unique product set, but also one based on both quality ingredients and solid intellectual property."
The Cannabis Global product portfolio includes the following:
Hemp You Can Feel™ Technology - Hemp You Can Feel™ infusions are among the most innovative in the hemp and cannabis sectors. Many of the Company's products are based on a unique cannabinoid delivery system using hemp extracts processed through honey bees; Bee fuse technology. The result is a truly water-soluble cannabinoid preparation utilizing no chemicals, surfactants or additives.
Hemp You Can Feel™ Coffee Product in Single Serving Pods - A line of single-serving coffee pods and instant coffees all powdered by the Company's Hemp You Can Feel™ infusion technologies. The single-serving coffee products have been accepted on the Amazon platform with production currently underway.
Hemp You Can Feel™ Instant Coffees - Using the same infusions that power the single-serving coffee pods, Cannabis Global has developed three instant coffee blends, which will be marketed alongside the other coffee products.
Hemp You Can Feel™ Alcohol Replacement Cocktail Mixers - The Company recently introduced Hemp You Can Feel™ cocktail mixers, an infusion technology that provides unparalleled relaxation while allowing the consumer to avoid the negative health effects of alcohol consumption. The technology is based on a manufacturing process that is all-natural and relies on no chemical surfactants, stabilizers or additives in order to produce an infusion technology with virtually no detectable taste and excellent food and beverage integration characteristics.
Hemp & Booch Hemp You Can Feel™ Kombucha - The product line, which targets the high end of the craft inspired Kombucha market, is infused using a unique honey bee hemp extract technology. Rather than using hemp extracts produced in a laboratory, like many other manufacturers, Cannabis Global has based its 100% natural product line on extracts of hemp produced through Bee fuse technology by providing hemp extracts to honey bees, which in turn naturally process the extracts into a unique and naturally water-soluble infusion technology.
Hemp You Can Feel™ Sweeteners - Cannabis Global has completed the research and development phase for its Hemp You Can Feel™ line of sweeteners and coffee creamers. The product line will feature two low-calorie sweeteners, two organic natural sweeteners and two powdered non-dairy creamers. Each product will feature the company's provisional patent-pending Hemp You Can Feel™ technology, based on all-natural hemp infusions. With natural true water solubility, and sub-milligram levels of hemp extracts and natural terpenes, this version of the technology measures significantly less than one milligram of CBD per serving.
THC-V Tea and Beverages - In a market first, Cannabis Global has completed product development and has begun distribution of its unique tetrahydrocannabivarin (THC-V) coffee and tea products to product beta testers. The Company has integrated three internally developed technologies into the unique manufacturing process for the industry's first THC-V beverages. The first of these is the process developed by the Company to produce 65%+ loaded THC-V, controlled release nanoparticles utilizing laboratory-based, pharmaceutical-grade production equipment. The Company is also utilizing both its internally developed powderization and one-step dosing system, ensuring precise dosing and significantly faster production. The Company's Project Varin has produced meaningful technology breakthroughs, which have resulted in several provisional patent filings. Via these technological developments, the Company has been able to significantly reduce the cost of exotic cannabinoids on a per-serving basis resulting in an expected cost advantage of greater than 50%. Project Varin has recently been expanded to include rare cannabinoid Cannabinol (CBN).
"Our goal all among has been to produce a unique set of products and toward this goal, we believe we have directly hit the mark. Our product line is unique by way of not only the innovative use of cannabinoid sciences, but also relative to product purity and out use of the finest ingredients available for our product lines," added Mr. Tabatabaei. "Over the coming weeks, our investors and consumers will see our Company launch a considerable new set of marketing assets to bring this innovative product line into the marketplace."
$MCTC News--Products going to Market!
Cannabis Global Directs Focus to Marketing Phase with Innovate Hemp Extract Product Lines
LOS ANGELES, CA -- July 7, 2020 -- InvestorsHub NewsWire -- Cannabis Global, Inc. (OTC: MCTC) ("Cannabis Global" or the "Company"), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, announces the completion of initial product development of the Hemp You Can Feel™ product lines, and the launch of the next phase of the Company's operations, which will focus on bringing the product lines to the marketplace. Over the coming weeks, Cannabis Global will be launching several new product marketing initiatives designed to move its innovative hemp extract and rare cannabinoid products into the marketplace.
"It has been approximately one year since we reorganized the Company, which today is known as Cannabis Global, Inc. During the first year, we concentrated on designing products that are distinct from the competition with established advantageous barriers," commented CEO Arman Tabatabaei. "We are very pleased with the results in that we not only have a unique product set, but also one based on both quality ingredients and solid intellectual property."
The Cannabis Global product portfolio includes the following:
Hemp You Can Feel™ Technology - Hemp You Can Feel™ infusions are among the most innovative in the hemp and cannabis sectors. Many of the Company's products are based on a unique cannabinoid delivery system using hemp extracts processed through honey bees; Bee fuse technology. The result is a truly water-soluble cannabinoid preparation utilizing no chemicals, surfactants or additives.
Hemp You Can Feel™ Coffee Product in Single Serving Pods - A line of single-serving coffee pods and instant coffees all powdered by the Company's Hemp You Can Feel™ infusion technologies. The single-serving coffee products have been accepted on the Amazon platform with production currently underway.
Hemp You Can Feel™ Instant Coffees - Using the same infusions that power the single-serving coffee pods, Cannabis Global has developed three instant coffee blends, which will be marketed alongside the other coffee products.
Hemp You Can Feel™ Alcohol Replacement Cocktail Mixers - The Company recently introduced Hemp You Can Feel™ cocktail mixers, an infusion technology that provides unparalleled relaxation while allowing the consumer to avoid the negative health effects of alcohol consumption. The technology is based on a manufacturing process that is all-natural and relies on no chemical surfactants, stabilizers or additives in order to produce an infusion technology with virtually no detectable taste and excellent food and beverage integration characteristics.
Hemp & Booch Hemp You Can Feel™ Kombucha - The product line, which targets the high end of the craft inspired Kombucha market, is infused using a unique honey bee hemp extract technology. Rather than using hemp extracts produced in a laboratory, like many other manufacturers, Cannabis Global has based its 100% natural product line on extracts of hemp produced through Bee fuse technology by providing hemp extracts to honey bees, which in turn naturally process the extracts into a unique and naturally water-soluble infusion technology.
Hemp You Can Feel™ Sweeteners - Cannabis Global has completed the research and development phase for its Hemp You Can Feel™ line of sweeteners and coffee creamers. The product line will feature two low-calorie sweeteners, two organic natural sweeteners and two powdered non-dairy creamers. Each product will feature the company's provisional patent-pending Hemp You Can Feel™ technology, based on all-natural hemp infusions. With natural true water solubility, and sub-milligram levels of hemp extracts and natural terpenes, this version of the technology measures significantly less than one milligram of CBD per serving.
THC-V Tea and Beverages - In a market first, Cannabis Global has completed product development and has begun distribution of its unique tetrahydrocannabivarin (THC-V) coffee and tea products to product beta testers. The Company has integrated three internally developed technologies into the unique manufacturing process for the industry's first THC-V beverages. The first of these is the process developed by the Company to produce 65%+ loaded THC-V, controlled release nanoparticles utilizing laboratory-based, pharmaceutical-grade production equipment. The Company is also utilizing both its internally developed powderization and one-step dosing system, ensuring precise dosing and significantly faster production. The Company's Project Varin has produced meaningful technology breakthroughs, which have resulted in several provisional patent filings. Via these technological developments, the Company has been able to significantly reduce the cost of exotic cannabinoids on a per-serving basis resulting in an expected cost advantage of greater than 50%. Project Varin has recently been expanded to include rare cannabinoid Cannabinol (CBN).
"Our goal all among has been to produce a unique set of products and toward this goal, we believe we have directly hit the mark. Our product line is unique by way of not only the innovative use of cannabinoid sciences, but also relative to product purity and out use of the finest ingredients available for our product lines," added Mr. Tabatabaei. "Over the coming weeks, our investors and consumers will see our Company launch a considerable new set of marketing assets to bring this innovative product line into the marketplace."
$MCTC News--Products going to Market!
Cannabis Global Directs Focus to Marketing Phase with Innovate Hemp Extract Product Lines
LOS ANGELES, CA -- July 7, 2020 -- InvestorsHub NewsWire -- Cannabis Global, Inc. (OTC: MCTC) ("Cannabis Global" or the "Company"), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, announces the completion of initial product development of the Hemp You Can Feel™ product lines, and the launch of the next phase of the Company's operations, which will focus on bringing the product lines to the marketplace. Over the coming weeks, Cannabis Global will be launching several new product marketing initiatives designed to move its innovative hemp extract and rare cannabinoid products into the marketplace.
"It has been approximately one year since we reorganized the Company, which today is known as Cannabis Global, Inc. During the first year, we concentrated on designing products that are distinct from the competition with established advantageous barriers," commented CEO Arman Tabatabaei. "We are very pleased with the results in that we not only have a unique product set, but also one based on both quality ingredients and solid intellectual property."
The Cannabis Global product portfolio includes the following:
Hemp You Can Feel™ Technology - Hemp You Can Feel™ infusions are among the most innovative in the hemp and cannabis sectors. Many of the Company's products are based on a unique cannabinoid delivery system using hemp extracts processed through honey bees; Bee fuse technology. The result is a truly water-soluble cannabinoid preparation utilizing no chemicals, surfactants or additives.
Hemp You Can Feel™ Coffee Product in Single Serving Pods - A line of single-serving coffee pods and instant coffees all powdered by the Company's Hemp You Can Feel™ infusion technologies. The single-serving coffee products have been accepted on the Amazon platform with production currently underway.
Hemp You Can Feel™ Instant Coffees - Using the same infusions that power the single-serving coffee pods, Cannabis Global has developed three instant coffee blends, which will be marketed alongside the other coffee products.
Hemp You Can Feel™ Alcohol Replacement Cocktail Mixers - The Company recently introduced Hemp You Can Feel™ cocktail mixers, an infusion technology that provides unparalleled relaxation while allowing the consumer to avoid the negative health effects of alcohol consumption. The technology is based on a manufacturing process that is all-natural and relies on no chemical surfactants, stabilizers or additives in order to produce an infusion technology with virtually no detectable taste and excellent food and beverage integration characteristics.
Hemp & Booch Hemp You Can Feel™ Kombucha - The product line, which targets the high end of the craft inspired Kombucha market, is infused using a unique honey bee hemp extract technology. Rather than using hemp extracts produced in a laboratory, like many other manufacturers, Cannabis Global has based its 100% natural product line on extracts of hemp produced through Bee fuse technology by providing hemp extracts to honey bees, which in turn naturally process the extracts into a unique and naturally water-soluble infusion technology.
Hemp You Can Feel™ Sweeteners - Cannabis Global has completed the research and development phase for its Hemp You Can Feel™ line of sweeteners and coffee creamers. The product line will feature two low-calorie sweeteners, two organic natural sweeteners and two powdered non-dairy creamers. Each product will feature the company's provisional patent-pending Hemp You Can Feel™ technology, based on all-natural hemp infusions. With natural true water solubility, and sub-milligram levels of hemp extracts and natural terpenes, this version of the technology measures significantly less than one milligram of CBD per serving.
THC-V Tea and Beverages - In a market first, Cannabis Global has completed product development and has begun distribution of its unique tetrahydrocannabivarin (THC-V) coffee and tea products to product beta testers. The Company has integrated three internally developed technologies into the unique manufacturing process for the industry's first THC-V beverages. The first of these is the process developed by the Company to produce 65%+ loaded THC-V, controlled release nanoparticles utilizing laboratory-based, pharmaceutical-grade production equipment. The Company is also utilizing both its internally developed powderization and one-step dosing system, ensuring precise dosing and significantly faster production. The Company's Project Varin has produced meaningful technology breakthroughs, which have resulted in several provisional patent filings. Via these technological developments, the Company has been able to significantly reduce the cost of exotic cannabinoids on a per-serving basis resulting in an expected cost advantage of greater than 50%. Project Varin has recently been expanded to include rare cannabinoid Cannabinol (CBN).
"Our goal all among has been to produce a unique set of products and toward this goal, we believe we have directly hit the mark. Our product line is unique by way of not only the innovative use of cannabinoid sciences, but also relative to product purity and out use of the finest ingredients available for our product lines," added Mr. Tabatabaei. "Over the coming weeks, our investors and consumers will see our Company launch a considerable new set of marketing assets to bring this innovative product line into the marketplace."
$MCTC News this morning!
Cannabis Global Introduces "Hemp & Booch" Super Premium Kombucha - Powered by Hemp You Can Feel™
June 30 2020 - 08:00AM
InvestorsHub NewsWire
Cannabis Global Introduces "Hemp & Booch" Super Premium Kombucha - Powered by Hemp You Can Feel™
LOS ANGELES, CA -- June 30, 2020 -- InvestorsHub NewsWire -- Cannabis Global, Inc. (OTC: MCTC) ("Cannabis Global" or the "Company"), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, is excited to announce the launch of its newest line of branded products, Hemp & Booch Super Premium hemp-infused Kombucha, a revolution in the Kombucha beverage market built on the finest ingredients available and powered by the Company's Hemp You Can Feel™ infusions.
"Hemp & Booch not only sets the standard for taste and purity, but also for the relaxing effect provided by the Company's patent pending Hemp You Can Feel™ infusions," commented Arman Tabatabaei, Cannabis Global CEO. "Our new line is based on the best all-natural ingredients available, and we believe this comes across in the taste of the products, which are now available in sample quantities."
The product line, which targets the high end of the craft inspired Kombucha market, is infused using a unique honey bee hemp extract technology. Rather than using hemp extracts produced in a laboratory, like all other manufacturers, Cannabis Global has based its 100% natural product line on extracts of hemp produced by providing hemp extracts to honey bees, which in turn naturally process the extracts into a unique and naturally water-soluble infusion technology.
Management believes the market opportunity in the Kombucha space is underappreciated, especially given the Company's built-in advantages in hemp infusion technology. According to Grand View Research, the global kombucha market is anticipated to reach USD $7.05 billion by 2027, growing at a CAGR of 19.7% over the forecast period, with growth driven by rising consumer consciousness around healthy dietary inputs.
The Company will be initially introducing three Kombuchas powered by Hemp You Can Feel™ - Concord Grape & Vanilla Bean, Pineapple Mint, and Kalmbucha, a special nighttime blend based on an exotic, caffeine-free organic African tea.
The ingredient lists are as follows:
Concord Grape and Vanilla Bean - Ingredients: organic concord grape juice, organic vanilla bean, organic coconut water, organic ginger, honey from organic farms, hemp extracts processed from Apis Mellifera (Honey Bees), and trace amounts of organic inulin from vegetables, organic locust bean gum.
Pineapple Mint - Ingredients: organic coconut water, organic tea, organic pineapple juice, organic mint, honey from organic farms, hemp extracts processed from Apis Mellifera (Honey Bees), and trace amounts of organic inulin from vegetables, organic locust bean gum.
Kalmbucha - Ingredients: organic coconut water, organic caffeine-free African tea, organic tart cherry juice, organic lavender, honey from organic farms, hemp extracts processed from Apis Mellifera (Honey Bees), and trace amounts of organic inulin from vegetables, organic locust bean gum.
Mr. Tabatabaei continued, "We have gone all out relative to the ingredients and manufacturing processes utilized to produce this super-premium line. It is an authentic 'raw food' product, keeping true to the healthful philosophy behind Kombucha products. We believe we are the only manufacturer able to complete the entire manufacturing process for a hemp-infused Kombucha product at room temperature allowing for full enzyme and amino acid retention. After all, consumers drink Kombucha for its health benefits, and our customers deserve the best in terms of both ingredients and production process."
Hemp & Booch is already available in sample quantities by request and will be available in commercial quantities through online distribution by the end of next month.
About Provisional Patent Filings
Under United States patent law, a provisional application is a legal document filed in the United States Patent and Trademark Office, that establishes an early filing date, but does not mature into an issued patent unless the applicant files a regular non-provisional patent application within one year.
About Cannabis Global, Inc.
Cannabis Global, Inc., formerly known as MCTC Holdings, Inc., is a fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading with the stock symbol MCTC. The Company is an emerging force in the area of cannabinoid sciences and highly bioavailable hemp and cannabis infusion technologies. The Company does not engage in the production, distribution, or sales of any controlled substances, including marijuana. The Company has an actively growing portfolio of intellectual property having filed six patents in the areas of cannabinoid delivery systems and cannabinoid polymeric nanoparticles. The Company markets its consumer products under the Hemp You Can Feel brand name. Cannabis Global launched its Project Varin early in 2020, to develop new delivery methods for rare cannabinoid Tetrahydrocannabivarin (THC-V) and to develop products based on this cannabinoid.
$MCTC News this morning!
Cannabis Global Introduces "Hemp & Booch" Super Premium Kombucha - Powered by Hemp You Can Feel™
June 30 2020 - 08:00AM
InvestorsHub NewsWire
Cannabis Global Introduces "Hemp & Booch" Super Premium Kombucha - Powered by Hemp You Can Feel™
LOS ANGELES, CA -- June 30, 2020 -- InvestorsHub NewsWire -- Cannabis Global, Inc. (OTC: MCTC) ("Cannabis Global" or the "Company"), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, is excited to announce the launch of its newest line of branded products, Hemp & Booch Super Premium hemp-infused Kombucha, a revolution in the Kombucha beverage market built on the finest ingredients available and powered by the Company's Hemp You Can Feel™ infusions.
"Hemp & Booch not only sets the standard for taste and purity, but also for the relaxing effect provided by the Company's patent pending Hemp You Can Feel™ infusions," commented Arman Tabatabaei, Cannabis Global CEO. "Our new line is based on the best all-natural ingredients available, and we believe this comes across in the taste of the products, which are now available in sample quantities."
The product line, which targets the high end of the craft inspired Kombucha market, is infused using a unique honey bee hemp extract technology. Rather than using hemp extracts produced in a laboratory, like all other manufacturers, Cannabis Global has based its 100% natural product line on extracts of hemp produced by providing hemp extracts to honey bees, which in turn naturally process the extracts into a unique and naturally water-soluble infusion technology.
Management believes the market opportunity in the Kombucha space is underappreciated, especially given the Company's built-in advantages in hemp infusion technology. According to Grand View Research, the global kombucha market is anticipated to reach USD $7.05 billion by 2027, growing at a CAGR of 19.7% over the forecast period, with growth driven by rising consumer consciousness around healthy dietary inputs.
The Company will be initially introducing three Kombuchas powered by Hemp You Can Feel™ - Concord Grape & Vanilla Bean, Pineapple Mint, and Kalmbucha, a special nighttime blend based on an exotic, caffeine-free organic African tea.
The ingredient lists are as follows:
Concord Grape and Vanilla Bean - Ingredients: organic concord grape juice, organic vanilla bean, organic coconut water, organic ginger, honey from organic farms, hemp extracts processed from Apis Mellifera (Honey Bees), and trace amounts of organic inulin from vegetables, organic locust bean gum.
Pineapple Mint - Ingredients: organic coconut water, organic tea, organic pineapple juice, organic mint, honey from organic farms, hemp extracts processed from Apis Mellifera (Honey Bees), and trace amounts of organic inulin from vegetables, organic locust bean gum.
Kalmbucha - Ingredients: organic coconut water, organic caffeine-free African tea, organic tart cherry juice, organic lavender, honey from organic farms, hemp extracts processed from Apis Mellifera (Honey Bees), and trace amounts of organic inulin from vegetables, organic locust bean gum.
Mr. Tabatabaei continued, "We have gone all out relative to the ingredients and manufacturing processes utilized to produce this super-premium line. It is an authentic 'raw food' product, keeping true to the healthful philosophy behind Kombucha products. We believe we are the only manufacturer able to complete the entire manufacturing process for a hemp-infused Kombucha product at room temperature allowing for full enzyme and amino acid retention. After all, consumers drink Kombucha for its health benefits, and our customers deserve the best in terms of both ingredients and production process."
Hemp & Booch is already available in sample quantities by request and will be available in commercial quantities through online distribution by the end of next month.
About Provisional Patent Filings
Under United States patent law, a provisional application is a legal document filed in the United States Patent and Trademark Office, that establishes an early filing date, but does not mature into an issued patent unless the applicant files a regular non-provisional patent application within one year.
About Cannabis Global, Inc.
Cannabis Global, Inc., formerly known as MCTC Holdings, Inc., is a fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading with the stock symbol MCTC. The Company is an emerging force in the area of cannabinoid sciences and highly bioavailable hemp and cannabis infusion technologies. The Company does not engage in the production, distribution, or sales of any controlled substances, including marijuana. The Company has an actively growing portfolio of intellectual property having filed six patents in the areas of cannabinoid delivery systems and cannabinoid polymeric nanoparticles. The Company markets its consumer products under the Hemp You Can Feel brand name. Cannabis Global launched its Project Varin early in 2020, to develop new delivery methods for rare cannabinoid Tetrahydrocannabivarin (THC-V) and to develop products based on this cannabinoid.
$MCTC News this morning!
Cannabis Global Introduces "Hemp & Booch" Super Premium Kombucha - Powered by Hemp You Can Feel™
June 30 2020 - 08:00AM
InvestorsHub NewsWire
Cannabis Global Introduces "Hemp & Booch" Super Premium Kombucha - Powered by Hemp You Can Feel™
LOS ANGELES, CA -- June 30, 2020 -- InvestorsHub NewsWire -- Cannabis Global, Inc. (OTC: MCTC) ("Cannabis Global" or the "Company"), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, is excited to announce the launch of its newest line of branded products, Hemp & Booch Super Premium hemp-infused Kombucha, a revolution in the Kombucha beverage market built on the finest ingredients available and powered by the Company's Hemp You Can Feel™ infusions.
"Hemp & Booch not only sets the standard for taste and purity, but also for the relaxing effect provided by the Company's patent pending Hemp You Can Feel™ infusions," commented Arman Tabatabaei, Cannabis Global CEO. "Our new line is based on the best all-natural ingredients available, and we believe this comes across in the taste of the products, which are now available in sample quantities."
The product line, which targets the high end of the craft inspired Kombucha market, is infused using a unique honey bee hemp extract technology. Rather than using hemp extracts produced in a laboratory, like all other manufacturers, Cannabis Global has based its 100% natural product line on extracts of hemp produced by providing hemp extracts to honey bees, which in turn naturally process the extracts into a unique and naturally water-soluble infusion technology.
Management believes the market opportunity in the Kombucha space is underappreciated, especially given the Company's built-in advantages in hemp infusion technology. According to Grand View Research, the global kombucha market is anticipated to reach USD $7.05 billion by 2027, growing at a CAGR of 19.7% over the forecast period, with growth driven by rising consumer consciousness around healthy dietary inputs.
The Company will be initially introducing three Kombuchas powered by Hemp You Can Feel™ - Concord Grape & Vanilla Bean, Pineapple Mint, and Kalmbucha, a special nighttime blend based on an exotic, caffeine-free organic African tea.
The ingredient lists are as follows:
Concord Grape and Vanilla Bean - Ingredients: organic concord grape juice, organic vanilla bean, organic coconut water, organic ginger, honey from organic farms, hemp extracts processed from Apis Mellifera (Honey Bees), and trace amounts of organic inulin from vegetables, organic locust bean gum.
Pineapple Mint - Ingredients: organic coconut water, organic tea, organic pineapple juice, organic mint, honey from organic farms, hemp extracts processed from Apis Mellifera (Honey Bees), and trace amounts of organic inulin from vegetables, organic locust bean gum.
Kalmbucha - Ingredients: organic coconut water, organic caffeine-free African tea, organic tart cherry juice, organic lavender, honey from organic farms, hemp extracts processed from Apis Mellifera (Honey Bees), and trace amounts of organic inulin from vegetables, organic locust bean gum.
Mr. Tabatabaei continued, "We have gone all out relative to the ingredients and manufacturing processes utilized to produce this super-premium line. It is an authentic 'raw food' product, keeping true to the healthful philosophy behind Kombucha products. We believe we are the only manufacturer able to complete the entire manufacturing process for a hemp-infused Kombucha product at room temperature allowing for full enzyme and amino acid retention. After all, consumers drink Kombucha for its health benefits, and our customers deserve the best in terms of both ingredients and production process."
Hemp & Booch is already available in sample quantities by request and will be available in commercial quantities through online distribution by the end of next month.
About Provisional Patent Filings
Under United States patent law, a provisional application is a legal document filed in the United States Patent and Trademark Office, that establishes an early filing date, but does not mature into an issued patent unless the applicant files a regular non-provisional patent application within one year.
About Cannabis Global, Inc.
Cannabis Global, Inc., formerly known as MCTC Holdings, Inc., is a fully audited and reporting Company with the U.S. Securities & Exchange Commission, trading with the stock symbol MCTC. The Company is an emerging force in the area of cannabinoid sciences and highly bioavailable hemp and cannabis infusion technologies. The Company does not engage in the production, distribution, or sales of any controlled substances, including marijuana. The Company has an actively growing portfolio of intellectual property having filed six patents in the areas of cannabinoid delivery systems and cannabinoid polymeric nanoparticles. The Company markets its consumer products under the Hemp You Can Feel brand name. Cannabis Global launched its Project Varin early in 2020, to develop new delivery methods for rare cannabinoid Tetrahydrocannabivarin (THC-V) and to develop products based on this cannabinoid.
Nice 3vil! This is an excellent article on $MCTC dated today.
https://www.mmjobserver.com/the-next-chapter-in-the-cbd-story-ycbd-nept-mctc-cvsi-cwbhf/33727/
wire
Excellent News Doog!
wire
$MCTC News this morning--Cannabis Global Extends and Expands Project Varin to Include Cannabinol (CBN)
June 11 2020
Cannabis Global, Inc. (OTC: MCTC) ("Cannabis Global" or the "Company"), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, is pleased to announce the expansion of its Project Varin research and development effort to include Cannabinol (CBN), under the umbrella of patent pending polymeric nanoparticle and nanofiber technologies developed for Tetrahydrocannabivarin (THC-V).
The first stage of Project Varin produced high load particles of pure THC-V, allowing the Company to now move into production of commercial quantities. As part of this second phase, CBN has been added to the production protocol.
"The addition of CBN to the Project Varin production schedule is an important test of our internally developed technologies," commented Arman Tabatabaei, CEO of the Company. "We believe the production parameters developed for THC-V will apply to CBN and other manufactured cannabinoids and we will be testing this premise on our currently scheduled manufacturing run. This will be an important test of the flexibility of our manufacturing process and if successful should allow us low cost leadership over a variety of rare cannabinoids."
Cannabinol is found in trace amounts in hemp plants and is often found in aged hemp. Unlike most cannabinoids, CBN does not stem directly from cannabinol (CBN), but occurs as cannabis is exposed to air or ultraviolet light for an extended period of time. While not as rare or as difficult to obtain as THC-V, CBN is still priced at a significant premium to more commonly found cannabinoids, such as CBD. Therefore, the production of high load polymeric nanoparticles based on the Company technologies could yield considerable flexibility and cost savings relative to the formulation of new cannabinoid products.
Mr. Tabatabaei continued, "We are committed to maintaining a leadership position in this area that will extend beyond core technologies and into the product arena. A successful test of CBN via our manufacturing processes will allow us to create new CBN products to complement our THC-V tea and coffee line, which is currently in pre-release testing with customers. As we have previously indicated, we believe our manufacturing techniques will yield a low-cost manufacturing position, while also setting the standard for product purity."
THC-V and CBN are not scheduled at the federal level. The Company's THC-V products contain zero tetrahydrocannabinol (THC), far below the acceptable federal level of 0.3%, and zero heavy metals, pesticide and herbicide residues, nitrates and other impurities that are contained in most cannabis and hemp products. The Company's products are not intended to diagnose, treat, cure or prevent any disease and are not for use by or sale to persons under the age of 18. The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product.
Product and technology developments were a result of the Company's Project Varin, which was implemented last year to invent new manufacturing and infusion technologies for rare cannabinoids, such as THC-V and CBN. The Company plans to utilize the developed technologies in similar applications for other rare cannabinoids.
$MCTC News this morning--Cannabis Global Extends and Expands Project Varin to Include Cannabinol (CBN)
June 11 2020
Cannabis Global, Inc. (OTC: MCTC) ("Cannabis Global" or the "Company"), a cannabinoid and hemp extract science-forward company developing infusion and delivery technologies, is pleased to announce the expansion of its Project Varin research and development effort to include Cannabinol (CBN), under the umbrella of patent pending polymeric nanoparticle and nanofiber technologies developed for Tetrahydrocannabivarin (THC-V).
The first stage of Project Varin produced high load particles of pure THC-V, allowing the Company to now move into production of commercial quantities. As part of this second phase, CBN has been added to the production protocol.
"The addition of CBN to the Project Varin production schedule is an important test of our internally developed technologies," commented Arman Tabatabaei, CEO of the Company. "We believe the production parameters developed for THC-V will apply to CBN and other manufactured cannabinoids and we will be testing this premise on our currently scheduled manufacturing run. This will be an important test of the flexibility of our manufacturing process and if successful should allow us low cost leadership over a variety of rare cannabinoids."
Cannabinol is found in trace amounts in hemp plants and is often found in aged hemp. Unlike most cannabinoids, CBN does not stem directly from cannabinol (CBN), but occurs as cannabis is exposed to air or ultraviolet light for an extended period of time. While not as rare or as difficult to obtain as THC-V, CBN is still priced at a significant premium to more commonly found cannabinoids, such as CBD. Therefore, the production of high load polymeric nanoparticles based on the Company technologies could yield considerable flexibility and cost savings relative to the formulation of new cannabinoid products.
Mr. Tabatabaei continued, "We are committed to maintaining a leadership position in this area that will extend beyond core technologies and into the product arena. A successful test of CBN via our manufacturing processes will allow us to create new CBN products to complement our THC-V tea and coffee line, which is currently in pre-release testing with customers. As we have previously indicated, we believe our manufacturing techniques will yield a low-cost manufacturing position, while also setting the standard for product purity."
THC-V and CBN are not scheduled at the federal level. The Company's THC-V products contain zero tetrahydrocannabinol (THC), far below the acceptable federal level of 0.3%, and zero heavy metals, pesticide and herbicide residues, nitrates and other impurities that are contained in most cannabis and hemp products. The Company's products are not intended to diagnose, treat, cure or prevent any disease and are not for use by or sale to persons under the age of 18. The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. Please consult your health care professional about potential interactions or other possible complications before using any product.
Product and technology developments were a result of the Company's Project Varin, which was implemented last year to invent new manufacturing and infusion technologies for rare cannabinoids, such as THC-V and CBN. The Company plans to utilize the developed technologies in similar applications for other rare cannabinoids.
Nice huge buys today!
Dropping more today, down to 3,300,000
https://iborrowdesk.com/report/CPE
It is listed above in the ibox for latest news.
https://ih.advfn.com/stock-market/NYSE/callon-petroleum-CPE/stock-news/82366981/callon-petroleum-company-schedules-first-quarter-2
2 milly short covered last 15 minutes. Could be on a good upswing here shortly.
https://iborrowdesk.com/report/CPE
They just covered 1.1 milly.
Slowly but surely, it looks like they are covering.
Wow, tremendous buying at .67
CPE Institution Holdings
The following table shows the largest shareholders in CALLON PETROLEUM CO COM (CPE) for the quarter ended March 31, 2020 , listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 03/31/2020
Institution Shares Shares % Last
Held Changed Held Report
BlackRock Fund Advisors 57,073,189 24,721,514 14.388 12/31
The Vanguard Group Inc. 41,098,129 17,383,387 10.360 12/31
Dimensional Fund Advisors LP 25,991,513 6,812,771 6.552 12/31
SSgA Funds Management Inc. 25,571,822 9,919,290 6.446 12/31
Goldman Sachs & Co. LLC (Priva 14,464,888 11,844,884 3.646 12/31
AQR Capital Management LLC 11,711,988 (1,448,268) 2.952 12/31
Barrow Hanley Mewhinney & St 11,107,193 3,463,357 2.800 12/31
Macquarie Investment Managemen 9,782,795 1,774,782 2.466 12/31
Columbia Management Investment 8,686,559 1,923,666 2.190 12/31
Lion Point Capital LP 8,202,705 8,202,705 2.068 12/31
Silvercrest Asset Management G 7,591,892 (208,343) 1.914 12/31
Northern Trust Investments In 7,445,933 1,992,456 1.877 12/31
Fisher Asset Management LLC 6,528,077 524,238 1.646 12/31
Franklin Advisers Inc. 6,378,703 406,737 1.608 12/31
Cramer Rosenthal McGlynn LLC 6,259,606 1,475,600 1.578 12/31
Arrowstreet Capital LP 6,058,357 3,311,657 1.527 12/31
Morgan Stanley & Co. LLC 6,055,117 4,577,152 1.526 12/31
Principal Global Investors LLC 5,285,970 3,219,625 1.333 12/31
Advisory Research Inc. 5,156,599 1,777,992 1.300 12/31
Geode Capital Management LLC 5,046,076 2,238,773 1.272 12/31
Voya Investment Management Co. 4,459,516 4,368,866 1.124 12/31
LSV Asset Management 3,861,984 3,861,984 0.974 12/31
Victory Capital Management In 3,848,673 (2,797,151) 0.970 12/31
Susquehanna Financial Group LL 3,844,680 2,612,473 0.969 12/31
Healthcare of Ontario Pension 3,834,194 3,834,194 0.967 12/31
American Century Investment Ma 3,821,281 350,716 0.963 12/31
Carlson Capital LP 3,704,174 240,474 0.934 12/31
Caymus Capital Partners LP 3,641,600 3,641,600 0.918 12/31
LMCG Investments LLC 3,508,282 1,480,813 0.884 12/31
Kennedy Capital Management In 3,395,308 450,189 0.856 12/31
Westwood Management Corp. (Tex 3,336,162 (1,939,466) 0.841 12/31
BNP Paribas Asset Management U 2,888,355 94,007 0.728 12/31
Glenmede Investment Management 2,856,737 2,856,737 0.720 12/31
Mellon Investments Corp. 2,825,277 1,177,516 0.712 12/31
UBS Securities LLC 2,822,431 2,822,431 0.712 12/31
Schroder Investment Management 2,702,338 184,848 0.681 12/31
Wells Capital Management Inc. 2,537,852 (655,623) 0.640 12/31
Nuveen Asset Management LLC 2,509,718 75,583 0.633 12/31
Charles Schwab Investment Mana 2,387,467 993,351 0.602 03/31
Palisade Capital Management LL 2,363,008 2,363,008 0.596 12/31
Natixis Investment Managers In 2,243,025 2,243,025 0.565 12/31
Voloridge Investment Managemen 2,206,896 881,608 0.556 12/31
William Blair Investment Manag 2,078,660 (1,670,551) 0.524 12/31
Millennium Management LLC 1,972,767 955,975 0.497 12/31
Investment Counselors of Maryl 1,943,147 1,943,147 0.490 12/31
Weiss Multi-Strategy Advisers 1,886,189 1,886,189 0.475 12/31
The Public Sector Pension Inve 1,874,687 1,297,387 0.473 12/31
Vaughan Nelson Investment Mana 1,826,992 (1,900,760) 0.461 12/31
BlackRock Investment Managemen 1,718,877 695,985 0.433 12/31
QMA LLC 1,642,829 207,829 0.414 12/31
Trump calls for U.S. oil industry bailout as prices plunge
WASHINGTON (Reuters) - U.S. President Donald Trump said on Tuesday he has asked his cabinet to devise a plan to inject cash into the ailing U.S. oil-drilling industry to help it survive a historic collapse in crude prices.
“We will never let the great U.S. Oil & Gas Industry down. I have instructed the Secretary of Energy and Secretary of the Treasury to formulate a plan which will make funds available so that these very important companies and jobs will be secured long into the future!” Trump said on Twitter.
U.S. oil and gas companies from Texas to Wyoming have struggled to stave off bankruptcy amid worldwide stay-at-home orders and business stoppages spurred by the coronavirus outbreak that have obliterated global demand for fuel.
U.S. crude oil futures collapsed to trade in negative territory for the first time in history on Monday, as desperate traders paid to get rid of barrels amid a dearth of storage space.
Last week, U.S. Energy Secretary Dan Brouillette told Reuters he was working with Treasury Secretary Steve Mnuchin to roughly double the size-limit on loans available to mid-tier U.S. energy companies under the recently passed CARES Act stimulus package to $200 million-$250 million.
He added he and Mnuchin also planned to work with U.S. regulators banks in hopes of ensuring continued access to credit for the U.S. oil and gas industry, which is estimated to owe more than $200 billion to lenders through loans backed by oil and gas reserves.
As revenue has plummeted and assets have declined in value, some companies are saying they may be unable to repay.
Whiting Petroleum Corp became the first major producer to file for Chapter 11 bankruptcy on April 1. Others, including Chesapeake Energy Corp, Denbury Resources Inc and Callon Petroleum Co, have hired debt advisers.
Oil prices have crashed as demand has shrunk due to lockdowns and economic slowdowns during the coronavirus pandemic. The Organization of the Petroleum Exporting Countries and its allies, including Russia, recently announced sweeping cuts in production, amounting to almost 10% of global supplies. Demand has dropped as much as 30%.
Kremlin spokesman Dmitry Peskov said leading global oil producers could hold talks again to discuss their output deal further if needed.
Trump has separately announce plans to fill up the U.S. Strategic Petroleum Reserve, something that would take around 77 million barrels off the market - or less than a day of typical global demand.
Congress so far has declined to provide the funding due to opposition from Democrats who oppose aiding the oil industry when laid-off workers and other sectors also need help.
Brouillette said on Tuesday he would meet with lawmakers in the U.S. House of Representatives to renew the administration call for funds to buy oil.
In the meantime, the Department of Energy is in talks with oil companies to lease some of the available space.
Trump has also repeatedly threatened to use tariffs to block crude oil imports to help domestic drillers - but the U.S. energy industry’s main trade associations have opposed the move, saying it would only raise costs for the refining sector.
https://www.reuters.com/article/us-global-oil-trump/trump-calls-for-us-oil-industry-bailout-as-prices-plunge-idUSKCN2231Z6
Why the drastic sell off?
Picking up a boatload more here too.
wire
Totally agree
HUGE news on $AYTU this morning!
NEWS-Cash-and-Cash-Equivalents-of-Approximately-$62.5-on-March-31, 2020
ENGLEWOOD, CO / ACCESSWIRE / April 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced that it has received over the preceding three weeks over $23.0 million in cash proceeds from warrant exercises with prices ranging from $1.25 to $1.50 . The warrants had a weighted-average exercise price of $1.35 . In total, approximately 17.1 million warrants were exercised.
The Company also announced a cash balance (unaudited) of approximately $62.5 Million as of March 31, 2020 . Financial statements for the quarter ending March 31, 2020 are expected to be released the week of May 11, 2020 .
About Aytu BioScience, Inc.
Aytu BioScience, Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking.
Aytu recently acquired Innovus Pharmaceuticals , a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the Company's proprietary Beyond Human® marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the Company's consumer healthcare products.
This is HUGE news on $AYTU this morning!
NEWS-Cash-and-Cash-Equivalents-of-Approximately-$62.5-on-March-31, 2020
ENGLEWOOD, CO / ACCESSWIRE / April 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced that it has received over the preceding three weeks over $23.0 million in cash proceeds from warrant exercises with prices ranging from $1.25 to $1.50 . The warrants had a weighted-average exercise price of $1.35 . In total, approximately 17.1 million warrants were exercised.
The Company also announced a cash balance (unaudited) of approximately $62.5 Million as of March 31, 2020 . Financial statements for the quarter ending March 31, 2020 are expected to be released the week of May 11, 2020 .
About Aytu BioScience, Inc.
Aytu BioScience, Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The Company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking.
Aytu recently acquired Innovus Pharmaceuticals , a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the Company's proprietary Beyond Human® marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the Company's consumer healthcare products.
NEWS -- Aytu Featured on NBC and Fox News (VIDEO): "Denver officers, firefighters will be among first in US to get rapid COVID-19 tests"; "Denver scores 2,700 COVID-19 rapid tests for first responders"
100,000 COVID-19 Rapid Tests Ready to Ship Across the Country with 500,000 More on the Way
ENGLEWOOD, CO / ACCESSWIRE / April 6, 2020 / Aytu BioScience, Inc. (AYTU), (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs was featured on a FOX segment titled: "Denver officers, firefighters will be among first in US to get rapid COVID-19 tests," reported on by affiliated television station in Denver, Colorado, KDVR; and on an NBC segment titled "Denver scores 2,700 COVID-19 rapid tests for first responders - Aytu Bioscience in Englewood has 100,000 tests ready to ship across the country with 500,000 more on the way," reported on by affiliated television station in Denver, Colorado, 9News.
To view the video segments in their entirety and to read the articles, please visit the links below:
FOX (VIDEO & Article)
https://kdvr.com/news/coronavirus/denver-officers-firefighters-will-be-among-first-in-us-to-get-rapid-covid-19-tests/
NBC (VIDEO & Article)
https://www.9news.com/article/news/denver-scores-2700-covid-19-rapid-tests-for-first-responders/73-29d83678-b8a3-4ec6-97ee-0829add97134
The COVID-19 IgG/IgM Rapid Test is a serology test used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 126 patient clinical trial in China and is CE marked.
The Company believes that serology tests are a potentially powerful tool for identifying anyone who has been infected, whether they had symptoms or not. Antibodies to coronaviruses typically remain in humans for up to 90 days or more. The Company believes that serological testing is important in identifying the total number of people who have been infected with COVID-19. This type of testing could be particularly important for the immune surveillance of health care workers, first responders, government workers, and others whose infection risks could be heightened by working with COVID-19 infected individuals.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking.
Aytu recently acquired Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human® marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.
NEWS -- Aytu Featured on NBC and Fox News (VIDEO): "Denver officers, firefighters will be among first in US to get rapid COVID-19 tests"; "Denver scores 2,700 COVID-19 rapid tests for first responders"
100,000 COVID-19 Rapid Tests Ready to Ship Across the Country with 500,000 More on the Way
ENGLEWOOD, CO / ACCESSWIRE / April 6, 2020 / Aytu BioScience, Inc. (AYTU), (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs was featured on a FOX segment titled: "Denver officers, firefighters will be among first in US to get rapid COVID-19 tests," reported on by affiliated television station in Denver, Colorado, KDVR; and on an NBC segment titled "Denver scores 2,700 COVID-19 rapid tests for first responders - Aytu Bioscience in Englewood has 100,000 tests ready to ship across the country with 500,000 more on the way," reported on by affiliated television station in Denver, Colorado, 9News.
To view the video segments in their entirety and to read the articles, please visit the links below:
FOX (VIDEO & Article)
https://kdvr.com/news/coronavirus/denver-officers-firefighters-will-be-among-first-in-us-to-get-rapid-covid-19-tests/
NBC (VIDEO & Article)
https://www.9news.com/article/news/denver-scores-2700-covid-19-rapid-tests-for-first-responders/73-29d83678-b8a3-4ec6-97ee-0829add97134
The COVID-19 IgG/IgM Rapid Test is a serology test used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 126 patient clinical trial in China and is CE marked.
The Company believes that serology tests are a potentially powerful tool for identifying anyone who has been infected, whether they had symptoms or not. Antibodies to coronaviruses typically remain in humans for up to 90 days or more. The Company believes that serological testing is important in identifying the total number of people who have been infected with COVID-19. This type of testing could be particularly important for the immune surveillance of health care workers, first responders, government workers, and others whose infection risks could be heightened by working with COVID-19 infected individuals.
About Aytu BioScience, Inc.
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto®, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist™, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra® XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) AcipHex® Sprinkle™, a granule formulation of rabeprazole sodium, a commonly prescribed proton pump inhibitor; (ii) Cefaclor, a second-generation cephalosporin antibiotic suspension; (iii) Karbinal® ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iv) Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu recently acquired exclusive U.S. distribution rights to the COVID-19 IgG/IgM Rapid Test. This coronavirus test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and has received CE marking.
Aytu recently acquired Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human® marketing and sales platform.
Aytu's strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.
Nice article ratbike! Here's another article from Italy concerning AYTU:
Article Translation from Italian to English:
https://www.massa-critica.it/2020/04/un-test-veloce-per-il-covid19-distribuito-da-aytu-biosciences/
Aytu will provide the US military and government with millions of quick tests to diagnose Covid19 in minutes. This test is produced in China, but Aytu was the first to obtain the distribution license for the American market.
The test price is around $ 25 and could serve as a pass for workers who are negative. The company is also growing strongly on the stock exchange and there are analysts who expect an increase in sales of even 500% and a target price of $ 4 per share compared to $ 1.40 per share these days.
This is the scientific explanation from the FDA (the American health organization):
"The COVID-19 IgG / IgM rapid test is a solid phase immunochromatographic test used in the rapid, qualitative and differential detection of IgG and IgM antibodies compared to the new Covid19 in human blood, serum or plasma."
"The COVID-19 IgG / IgM rapid test licensed by Aytu is approved for distribution in the United States under the FDA's Emergency Use Authorization (EUA) policy."
"The COVID-19 IgG / IgM rapid test is intended for professional use only and provides clinical results between 2 and 10 minutes at the point of care by analyzing samples of individuals with signs and symptoms of SARS-CoV-2 infection. This test has been validated in a clinical study of 126 patients and is CE marked. "
The risks of an investment in AYTU are evident due to the high volatility of the security, but it is possible that in the long term, thanks to new technologies, the security can make exciting performances.
In the short term, the stock is very likely to grow: analysts from the Financial Times estimate a potential growth of even 300%.
The tests will surely be required to a large extent as long as we are dominated by the fear of Coronavirus.
wire
Very nice find Leftcoaster!
More $AYTU News out
XpresSpa Pursues Novel Coronavirus (COVID-19) Screening and Testing at U.S. Airports
April 3, 2020
Forms New Business Unit XpresTest
In Discussions for Initial Testing with Three Major Airports
NEW YORK, April 03, 2020 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), today provided an
update on recent discussions with local airport authorities and healthcare partners so that it may begin providing screening and testing for novel coronavirus (“COVID-19”) at U.S. airports. COVID-19 screening and testing would be conducted by converting select existing spa locations for this purpose on an interim basis and over time, potentially adding separate, standalone airport locations as testing sites.
XpresSpa’s U.S. airport real estate portfolio consists of 46 locations across 23 airports that are ready to be reactivated and redeployed in short order, subject to the approval of local airport authorities. The Company’s global spas are temporarily closed due to recent local government mandates categorizing its traditional services as “non-essential services”.
Since March 19, 2020, XpresSpa has been advancing discussions with healthcare partners to develop a model for COVID-19 screening and testing in U.S. airports as a much-needed public service. The Company has also recently filed paperwork in the State of Delaware to form a new business unit to administer such screening and testing capabilities, XpresTest, Inc., as a wholly-owned subsidiary of XpresSpa Group, Inc.
While nothing definitive has yet been finalized, XpresSpa is currently in discussions with three major airports, JFK International Airport, Hartsfield-Jackson Atlanta International Airport and Chicago O'Hare International Airport to pilot COVID-19 screening and testing for airline employees, contractors and workers, concessionaires and their employees, TSA agents, and U.S. Customs and Border Protection agents.
The Company is also in the process of recruiting a medical director who would work alongside healthcare officials to help design safe and compliant protocols and train employees.
Doug Satzman, Chief Executive Officer, XpresSpa said, “We are moving forward with our public and private relationships to make COVID-19
screening and testing in U.S. airports a reality and hopefully will be able to begin pilot testing shortly for the benefit and protection of our fellow citizens.
Since the onset of this pandemic, we have thought that we can and should play a significant role within the travel sector in the fight against COVID-19 and other highly contagious diseases in the future given our airport relationships, infrastructure, workforce with TSA clearance and strong desire to keep everyone safe.”
The Company recently announced its partnership with Relevant Healthcare. Relevant Healthcare is currently offering clinical diagnostic testing for COVID-19 through its contracts with Laboratory Corporation of America® (“LabCorp”) and Quest Diagnostics™ (“Quest”) to support full COVID-19 RT-PCR testing. In addition, the Company is also in active discussions with [Aytu BioScience (NASDAQ: AYTU; “Aytu”)], a specialty pharmaceutical company, and marketer of a COVID-19 IgG/IgM Rapid Test, and [Henry Schein Medical (“Henry Schein”)], the world’s largest distributor of health care solutions to office-based dental and medical professionals, and the developer of the Standard Q COVID-19 test, to deploy their respective rapid antibody blood testing solutions.
XpresSpa would also partner with Healthalytica, LLC (“Healthalytica”), a New York City-based provider of digital health and financial transparency solutions for health plans. Healthalytica would be charged with processing claims, insurance payments and distributing test result data to the appropriate local, state, and national authorities.
In developing its model for COVID-19 screening and testing at U.S. airports, XpresSpa is being assisted by Capstone Municipal Advisors LLC
(“Capstone”) who is serving as a project manager. Capstone is an Atlanta-based Minority Business Enterprise (“MBE”) that provides management consulting services and advice to state and local governments in the areas of municipal finance and infrastructure.
More $AYTU News!
XpresSpa Pursues Novel Coronavirus (COVID-19) Screening and Testing at U.S. Airports
April 3, 2020
Forms New Business Unit XpresTest
In Discussions for Initial Testing with Three Major Airports
NEW YORK, April 03, 2020 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), today provided an
update on recent discussions with local airport authorities and healthcare partners so that it may begin providing screening and testing for novel coronavirus (“COVID-19”) at U.S. airports. COVID-19 screening and testing would be conducted by converting select existing spa locations for this purpose on an interim basis and over time, potentially adding separate, standalone airport locations as testing sites.
XpresSpa’s U.S. airport real estate portfolio consists of 46 locations across 23 airports that are ready to be reactivated and redeployed in short order, subject to the approval of local airport authorities. The Company’s global spas are temporarily closed due to recent local government mandates categorizing its traditional services as “non-essential services”.
Since March 19, 2020, XpresSpa has been advancing discussions with healthcare partners to develop a model for COVID-19 screening and testing in U.S. airports as a much-needed public service. The Company has also recently filed paperwork in the State of Delaware to form a new business unit to administer such screening and testing capabilities, XpresTest, Inc., as a wholly-owned subsidiary of XpresSpa Group, Inc.
While nothing definitive has yet been finalized, XpresSpa is currently in discussions with three major airports, JFK International Airport, Hartsfield-Jackson Atlanta International Airport and Chicago O'Hare International Airport to pilot COVID-19 screening and testing for airline employees, contractors and workers, concessionaires and their employees, TSA agents, and U.S. Customs and Border Protection agents.
The Company is also in the process of recruiting a medical director who would work alongside healthcare officials to help design safe and compliant protocols and train employees.
Doug Satzman, Chief Executive Officer, XpresSpa said, “We are moving forward with our public and private relationships to make COVID-19
screening and testing in U.S. airports a reality and hopefully will be able to begin pilot testing shortly for the benefit and protection of our fellow citizens.
Since the onset of this pandemic, we have thought that we can and should play a significant role within the travel sector in the fight against COVID-19 and other highly contagious diseases in the future given our airport relationships, infrastructure, workforce with TSA clearance and strong desire to keep everyone safe.”
The Company recently announced its partnership with Relevant Healthcare. Relevant Healthcare is currently offering clinical diagnostic testing for COVID-19 through its contracts with Laboratory Corporation of America® (“LabCorp”) and Quest Diagnostics™ (“Quest”) to support full COVID-19 RT-PCR testing. In addition, the Company is also in active discussions with [Aytu BioScience (NASDAQ: AYTU; “Aytu”)], a specialty pharmaceutical company, and marketer of a COVID-19 IgG/IgM Rapid Test, and [Henry Schein Medical (“Henry Schein”)], the world’s largest distributor of health care solutions to office-based dental and medical professionals, and the developer of the Standard Q COVID-19 test, to deploy their respective rapid antibody blood testing solutions.
XpresSpa would also partner with Healthalytica, LLC (“Healthalytica”), a New York City-based provider of digital health and financial transparency solutions for health plans. Healthalytica would be charged with processing claims, insurance payments and distributing test result data to the appropriate local, state, and national authorities.
In developing its model for COVID-19 screening and testing at U.S. airports, XpresSpa is being assisted by Capstone Municipal Advisors LLC
(“Capstone”) who is serving as a project manager. Capstone is an Atlanta-based Minority Business Enterprise (“MBE”) that provides management consulting services and advice to state and local governments in the areas of municipal finance and infrastructure.
News -- Aytu BioScience Announces First Commercial Shipment of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test
First COVID-19 Rapid Tests Delivered to Denver First Responders
ENGLEWOOD, CO / ACCESSWIRE / April 3, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it began shipping its Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test to U.S. customers. Upon receipt of the initial 100,000 tests, the company completed product relabeling to ensure compliance with FDA guidance on COVID-19 serology test kits.
The Company has received orders for the COVID-19 IgG/IgM Rapid Test from a broad range of healthcare customers including large medical centers, municipalities, first responders, medical practices, and other healthcare customers. The Company expects to have all customer backorders filled in the coming days.
The Company's first 2,750 COVID-19 Rapid Tests have been purchased by the Denver Police Department for use in screening Denver's first responders. The test kits were delivered to Denver Chief of Police Paul Pazen and members of his leadership team at Aytu BioScience's corporate headquarters on April 2, 2020.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Upon receipt of our initial product shipment on March 31st, we immediately went to work to prepare the test kits for commercial distribution. The Aytu team has worked very hard over the last two days to relabel all 100,000 tests, and we're now shipping product to our customers across the country. Importantly, we are proud to be assisting our first responders here at home as we delivered over 2,000 tests to Denver Police Chief Pazen and his team. Our public safety personnel are doing outstanding work in our communities throughout this crisis, so we're glad to be partnering with Denver's first responders in this fight."
Mr. Disbrow continued, "The demand for the COVID-19 IgG/IgM Rapid Test has been substantial, so we have increased our order size to 500,000 tests (20,000 kits) to provide a larger supply to healthcare professionals and first responders in need."
The COVID-19 IgG/IgM Rapid Test is a serology test used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 126 patient clinical trial in China and is CE marked.
The Company believes that serology tests are a potentially powerful tool for identifying anyone who has been infected, whether they had symptoms or not. Antibodies to coronaviruses typically remain in humans for up to 90 days or more. The Company believes that serological testing is important in identifying the total number of people who have been infected with COVID-19. This type of testing could be particularly important for the immune surveillance of health care workers, first responders, government workers, and others whose infection risks could be heightened by working with COVID-19 infected individuals.
News -- Aytu BioScience Announces First Commercial Shipment of its 2-10 Minute COVID-19 IgG/IgM Point-of-Care Rapid Test
First COVID-19 Rapid Tests Delivered to Denver First Responders
ENGLEWOOD, CO / ACCESSWIRE / April 3, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it began shipping its Coronavirus Disease 2019 ("COVID-2019") IgG/IgM Rapid Test to U.S. customers. Upon receipt of the initial 100,000 tests, the company completed product relabeling to ensure compliance with FDA guidance on COVID-19 serology test kits.
The Company has received orders for the COVID-19 IgG/IgM Rapid Test from a broad range of healthcare customers including large medical centers, municipalities, first responders, medical practices, and other healthcare customers. The Company expects to have all customer backorders filled in the coming days.
The Company's first 2,750 COVID-19 Rapid Tests have been purchased by the Denver Police Department for use in screening Denver's first responders. The test kits were delivered to Denver Chief of Police Paul Pazen and members of his leadership team at Aytu BioScience's corporate headquarters on April 2, 2020.
Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "Upon receipt of our initial product shipment on March 31st, we immediately went to work to prepare the test kits for commercial distribution. The Aytu team has worked very hard over the last two days to relabel all 100,000 tests, and we're now shipping product to our customers across the country. Importantly, we are proud to be assisting our first responders here at home as we delivered over 2,000 tests to Denver Police Chief Pazen and his team. Our public safety personnel are doing outstanding work in our communities throughout this crisis, so we're glad to be partnering with Denver's first responders in this fight."
Mr. Disbrow continued, "The demand for the COVID-19 IgG/IgM Rapid Test has been substantial, so we have increased our order size to 500,000 tests (20,000 kits) to provide a larger supply to healthcare professionals and first responders in need."
The COVID-19 IgG/IgM Rapid Test is a serology test used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 126 patient clinical trial in China and is CE marked.
The Company believes that serology tests are a potentially powerful tool for identifying anyone who has been infected, whether they had symptoms or not. Antibodies to coronaviruses typically remain in humans for up to 90 days or more. The Company believes that serological testing is important in identifying the total number of people who have been infected with COVID-19. This type of testing could be particularly important for the immune surveillance of health care workers, first responders, government workers, and others whose infection risks could be heightened by working with COVID-19 infected individuals.
Hopefully, this link will show you that the AYTU test kit has 25 tests per kit. See Ordering Information at the bottom:
http://www.orientgene.com/asp-en/news/detail.aspx?id=8395
$AYTU 2,750 Rapid tests with COVID-19 results in 2 to 10 minutes being delivered by
@AytuBioscience
to
@DenverPolice
@DenverFireDept
@DenverSheriff
2,750 Rapid tests with COVID-19 results in 2 to 10 minutes being delivered by @AytuBioscience to @DenverPolice @DenverFireDept @DenverSheriff #kdvr pic.twitter.com/etxots3dBF
— Rob Low (@RobLowTV) April 2, 2020
$AYTU 2,750 Rapid tests with COVID-19 results in 2 to 10 minutes being delivered by
@AytuBioscience
to
@DenverPolice
@DenverFireDept
@DenverSheriff
2,750 Rapid tests with COVID-19 results in 2 to 10 minutes being delivered by @AytuBioscience to @DenverPolice @DenverFireDept @DenverSheriff #kdvr pic.twitter.com/etxots3dBF
— Rob Low (@RobLowTV) April 2, 2020
$AYTU- Boom! Distribution Tweet
Great work Rob!!!!
— Surfacetite (@D_Traitor) April 2, 2020
$AYTU- Boom! Distribution Tweet
Great work Rob!!!!
— Surfacetite (@D_Traitor) April 2, 2020
Look at the Ordering Information on this link (bottom).
http://www.orientgene.com/asp-en/news/detail.aspx?id=8395
Sweet reply! Keep the naysayers at bay.
wire